Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
Cellectar Biosciences Inc. (NASDAQ:CLRB) stock is trading lower Tuesday after the company shared results from its CLOVER WaM pivotal study.
纳斯达克的Cellectar Biosciences股票周二下跌，因该公司发布了其CLOVER Wam关键研究结果。
The study evaluated iopofosine I 131, a targeted radiotherapeutic candidate, for relapsed/refractory Waldenstrom's macroglobulinemia (WM) — a type of cancer that begins in the white blood cells.
该研究评估了狙击放射性候选药物Iopofosine I 131，用于复发/难治的沃尔登斯特龙巨球蛋白症（WM）——一种始发于白血细胞的癌症。
As of May 31, the CLOVER WaM study's results had an overall response rate (ORR) of 80% and a major response rate (MRR) of 56.4%. Results exceeded the agreed-upon primary endpoint of a 20% MRR.
截至5月31日，CLOVER Wam研究的结果显示总体反应率（ORR）为80％，主要反应率（MRR）为56.4％。结果超过了商定的20％MRR的主要终点。
The median number of prior lines of therapy was four, with approximately 27% of patients refractory to all available therapies and 40% of patients dual-class refractory.
治疗前的中位数为4条，约27％的患者对所有可用疗法具有难治性，40％的患者具有双类难治性。
In January, when the company reported early data, the CLOVER WaM study showed MRR of 61%, ORR of 75.6% in evaluable patients, and 100% experienced disease control.
一月份，当公司报告早期数据时，CLOVER Wam研究在可评估患者中显示出61％的MRR，75.6％的ORR和100％的疾病控制率。
The comparable ORRs were observed across all disease subgroups, including: MYD88-wt (81%; n=16), P53-mutated (80%; n=5), and clinical patient cohorts including post-BTKi (72%; n=39), as well as dual-class (59%; n=22), and triple-class (53%; n=15) refractory patients.
相似的ORR在所有疾病亚组中观察到，包括：MYD88-wt（81％; n = 16），P53-mutated（80％; n = 5）和临床患者队列，包括发帖-BTKi（72％; n = 39），以及双类（59％; n =22）和三类（53％; n = 15）难治患者。
Secondary endpoints of disease control rate (98.2%) and duration of response (DoR) presented evidence that iopofosine provided durable clinical benefit across all response categories.
疾病控制率的二级终点（98.2％）和反应持续时间（DoR）提供了证据，表明Iopofosine提供了所有反应类别的持久临床益处。
The median DoR in patients achieving major response and overall response were not reached as of the data cutoff, with 78% and 72% remaining free from disease progression at 18 months, respectively.
截至数据截止日期，取得主要反应和总体反应的患者的中位DoR尚未达到，分别为18个月，其中78％和72％仍然没有疾病进展。
The company plans to file an FDA marketing application in the fourth quarter of 2024.
该公司计划在2024年第四季度提交FDA营销申请。
Iopofosine I 131 was well tolerated and its toxicity profile was consistent with the company's previously reported safety data.
Iopofosine I 131被很好地耐受，并且其毒性特征与公司先前报告的安全数据一致。
Unlike other cancer therapies, patients on iopofosine did not experience any cardiovascular, renal, or liver toxicities.
与其他癌症治疗不同，接受Iopofosine治疗的患者没有经历心血管，肾脏或肝脏毒性。
The most commonly reported treatment-emergent adverse events were hematologic in nature (thrombocytopenia, neutropenia and anemia) and were predictable and manageable.
最常报告的治疗新发不良事件的性质为血液学（血小板减少症，中性粒细胞减少症和贫血症），可预测和可管理。
All patients recovered from cytopenias within a few weeks post nadir.
所有患者在达到最低点后的几周内从细胞减少症中恢复过来。
The company says that CLOVER WaM is the first and largest WM study to date in a highly refractory patient population.
该公司表示，CLOVER Wam是迄今为止高度难治人群中最大的Wm研究。
Price Action: CLRB stock was down 24.83% at $2.27 at last check Tuesday.
Milestone Scientific的股票CLRb周二最后一次检查下跌24.83％，至2.27美元。
- EXCLUSIVE: Milestone Scientific Announces Medicare Price Assignment For CompuFlo Epidural System For Back Pain Covering Additional US States.
- 独家：Milestone Scientific宣布，CompuFlo腰麻系统已获得美国医保价格分配，覆盖额外的美国州。